Amyotrophic Lateral Sclerosis PBMC

Amyotrophic Lateral Sclerosis PBMC for Neurodegeneration Research

Amyotrophic Lateral Sclerosis (ALS) PBMC products are sourced from IRB-consented donors clinically diagnosed with ALS and processed within 24 hours of collection under standardised conditions. ALS is a progressive neurodegenerative disease of the upper and lower motor neurons, characterised pathologically by cytoplasmic TDP-43 proteinopathy in the great majority of cases. These cryopreserved peripheral blood mononuclear cells support neurodegeneration research, peripheral immune characterisation and patient-derived cell model generation.

Motor Neuron Degeneration and What Peripheral Cells Contribute

  • ALS is a neurodegenerative disorder, not an autoimmune one. The core pathology is motor neuron loss with TDP-43 mislocalisation and aggregation, accompanied by glial activation in the central nervous system.
  • A subset of cases is familial, most commonly linked to the C9orf72 hexanucleotide repeat expansion and to variants in SOD1, TARDBP and FUS; PBMCs carry the donor genotype and so support genetic and functional follow-up.
  • Peripheral immune cells in ALS show altered activation and regulatory T cell profiles reported across multiple cohorts, positioning PBMCs as a tractable window on the neuroinflammatory component of disease.
  • PBMCs are a nucleated cell source, so they are appropriate for immunophenotyping by flow cytometry, single-cell and bulk transcriptomics, and functional stimulation assays.
  • PBMCs are widely used as a starting material for induced pluripotent stem cell reprogramming, enabling patient-derived motor neuron and glial models carrying the donor’s genetic background.
  • Monocyte and lymphocyte gene expression signatures are actively investigated as accessible peripheral correlates of disease progression, complementing CSF and neurofilament measures.

Donor Stratification Available

  • Sporadic versus familial ALS where documented
  • Known genotype where available, including C9orf72, SOD1, TARDBP and FUS
  • Site of onset: bulbar versus limb onset
  • Disease duration since symptom onset or diagnosis
  • Functional status and treatment history, including riluzole and edaravone where reported
  • Matched healthy controls available

Product Features

  • Research Use Only (RUO), cryopreserved PBMCs
  • Clinically confirmed ALS donors
  • Processed within 24 hours of collection
  • Stored using CryoStor® CS10 freezing media
  • Custom aliquot sizes available on request
  • IRB-approved protocols and electronic informed consent

De-identified Donor Data

  • Verified ALS diagnosis
  • Donor demographics: age, sex assigned at birth, race/ethnicity
  • Self-reported allergies and infectious disease history
  • Medication and treatment history where reported
  • Additional ALS-specific data available upon request

Applications

  • Immunophenotyping of lymphocyte, monocyte and regulatory T cell populations by flow cytometry
  • Bulk and single-cell RNA sequencing of peripheral immune populations
  • iPSC reprogramming and patient-derived motor neuron model generation
  • Genotyping and functional characterisation of ALS-associated variants
  • Neuroinflammation and cytokine release assay development
  • Peripheral biomarker discovery for disease progression
  • Drug screening and target engagement studies in patient-derived cells
  • Proteomic profiling of patient-derived mononuclear cells

Other Amyotrophic Lateral Sclerosis Specimen Types

Compliance and Quality Assurance

  • IRB-approved collections and protocols
  • 21 CFR Part 11 – compliant e-consent system
  • HIPAA-compliant donor data protection

Ordering & Customization

Amyotrophic Lateral Sclerosis PBMC samples are shipped on dry ice and available in custom aliquots. For pricing, current availability, international orders or regulatory requirements, please contact learnmore@sanguinebio.com to confirm documentation and compliance needs. To browse donor cohorts across our full inventory, visit our human PBMCs page.

Protocols & Documentation

  • PBMC Isolation from Whole Blood

    Standard operating procedure for isolating peripheral blood mononuclear cells from whole blood using density-gradient separation.

    Download
  • Immune Cell Isolation

    Guidelines for isolating immune cell populations with validated enrichment steps, purity checkpoints, and documentation.

    Download
  • Choosing the Right PBMC Configuration

    Reference guide comparing PBMC formats, cryopreservation states, and study-fit recommendations for your application.

    Download
  • Thawing Cryopreserved PBMC

    Validated thawing protocol to recover viable cryopreserved PBMCs while minimizing activation and loss of function.

    Download
  • Informed Consent Form (ICF)

    Available upon request — confirms donor consent for research use and downstream commercialization.

PBMC

Frequently Asked Questions

Showing 1–12 of 30 results

Are samples IRB approved?

1 Answer

YES – All collections are conducted under IRB-approved protocols and electronic informed consent. Sanguine utilizes Advarra and WCG IRB for oversight.

YES – all our products are research use only (RUO).

Storage depends on sample type but often cryopreserved samples stored in liquid nitrogen can be stored for years.

Extensive customization is available. To discuss your project request a quote or email us at learnmore@sanguinebio.com.

Sanguine offers flexible prospective collection services tailored to fit your research. For more information and to request a quote, please see: our prospective biospecimen collection services page.

Timelines depend on condition, sample type, and I/E criteria but we often start collection within 2 weeks of signed agreement.

YES – we have in-stock inventory. You can also email us at learnmore@sanguinebio.com as we continually get new samples in our inventory.

Each sample from a different individual – Unique donor means each sample comes from a different person, ensuring biological diversity in your study.

YES – Unique donors can be specified and guaranteed based on your requirements.

For information about sample quality, please see: Quality and Compliance

YES – “IRB-approved collection protocols” and IRB approval documentation available upon request. Sanguine utilizes two internationally-recognized IRBs (Advarra and WCG IRB) for review and approval.

1
×

Ask a Question

Need a custom PBMC cohort?

Our scientific team can scope prospective collections with donor-specific I/E criteria, typically starting within 2 weeks of agreement.

More Information